临床实践
Copyright ©The Author(s) 2024.
世界华人消化杂志. 2024-11-28; 32(11): 843-850
在线出版 2024-11-28. doi: 10.11569/wcjd.v32.i11.843
表2 不同临床病理参数患者△CT值及miR-10a、miR-21(mean±SD)
项目例数动脉期△CT值(HU)静脉期△CT值(HU)延迟期△CT值(HU)miR-10amiR-21
性别
5220.65±5.5623.53±4.4614.98±3.344.72±1.345.07±1.35
4820.90±5.3123.80±4.1215.77±2.894.80±1.125.15±1.21
t, P0.230, 0.8200.314, 0.7541.260, 0.2110.323, 0.7480.311, 0.756
年龄(岁)
<605520.49±5.4822.99±5.5015.12±4.154.59±1.265.10±1.02
≥604521.11±4.9624.48±3.9815.65±3.734.97±1.055.12±1.49
t, P0.587, 0.5581.520, 0.1320.665, 0.5081.615, 0.1100.080, 0.937
肿瘤直径(cm)
<44918.51±3.3520.04±3.8913.35±1.864.11±1.024.30±1.38
≥45122.94±4.1627.14±4.2517.29±3.405.38±1.485.89±1.60
t, P5.851, <0.0018.704, <0.0017.148, <0.0014.977, <0.0015.312, <0.001
分化程度
低分化2624.73±4.4227.14±4.1218.89±1.685.63±1.575.92±1.53
中分化3620.62±3.2823.58±3.5615.30±1.404.70±1.235.09±1.42
高分化3818.20±2.9421.35±2.6513.00±1.244.22±1.004.57±1.13
F, P26.998, <0.00122.271, <0.001132.538, <0.0019.884, <0.0017.743, <0.001
TNM分期
Ⅰ期4218.05±3.1719.95±2.6513.01±3.013.96±1.424.35±1.43
Ⅱ期5822.74±4.5826.35±3.8717.06±3.785.34±1.865.66±1.61
t, P5.715, <0.0019.255, <0.0015.746, <0.0014.030, <0.0014.206, <0.001
肿瘤位置
上段1920.80±4.4623.70±3.3415.40±3.764.82±1.515.08±1.44
中段3920.75±4.5723.63±3.1915.38±3.854.72±1.665.10±1.42
下段4220.78±4.5023.67±3.4015.32±4.114.77±1.625.13±1.40
F, P0.001, 0.9990.003, 0.9970.004, 0.9960.026, 0.9740.009, 0.991
血管侵犯
4423.34±5.3926.12±4.4817.53±4.255.45±1.345.60±1.46
5618.75±3.4521.73±3.0113.66±3.114.22±1.054.73±1.33
t, P5.170, <0.0015.847, <0.0015.257, <0.0015.148, <0.0013.110, <0.001
神经侵犯
4022.89±4.6825.87±4.4616.89±3.975.53±1.425.74±1.51
6019.36±3.1722.19±3.2514.34±2.034.25±1.574.69±1.30
t, P4.500, <0.0014.772, <0.0014.222, <0.0014.147, <0.0013.708, <0.001

引文著录: 夏玲燕, 徐诚成, 倪丽欣. 增强CT参数及miR-10a、miR-21在直肠癌中表达及意义. 世界华人消化杂志 2024; 32(11): 843-850